Annovis Bio Statistics
Total Valuation
Annovis Bio has a market cap or net worth of $109.13 million. The enterprise value is $105.13 million.
| Market Cap | 109.13M |
| Enterprise Value | 105.13M |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Annovis Bio has 13.05 million shares outstanding. The number of shares has increased by 22.09% in one year.
| Shares Outstanding | 13.05M |
| Shares Change (YoY) | +22.09% |
| Shares Change (QoQ) | +4.46% |
| Owned by Insiders (%) | 21.56% |
| Owned by Institutions (%) | 7.74% |
| Float | 10.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.24
| Current Ratio | 1.24 |
| Quick Ratio | 0.99 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -453.01% and return on invested capital (ROIC) is -269.05%.
| Return on Equity (ROE) | -453.01% |
| Return on Assets (ROA) | -183.39% |
| Return on Capital (ROIC) | -269.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.69M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.84% in the last 52 weeks. The beta is 1.73, so Annovis Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.73 |
| 52-Week Price Change | -18.84% |
| 50-Day Moving Average | 9.41 |
| 200-Day Moving Average | 9.77 |
| Relative Strength Index (RSI) | 47.25 |
| Average Volume (20 Days) | 173,387 |
Short Selling Information
The latest short interest is 1.26 million, so 9.63% of the outstanding shares have been sold short.
| Short Interest | 1.26M |
| Short Previous Month | 1.48M |
| Short % of Shares Out | 9.63% |
| Short % of Float | 12.28% |
| Short Ratio (days to cover) | 4.85 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -40.88M |
| Pretax Income | -47.53M |
| Net Income | -43.02M |
| EBITDA | n/a |
| EBIT | -40.88M |
| Earnings Per Share (EPS) | -$5.26 |
Balance Sheet
| Cash & Cash Equivalents | 4.00M |
| Total Debt | n/a |
| Net Cash | 4.00M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | -1.75M |
| Book Value Per Share | -0.15 |
| Working Capital | 989,116 |
Cash Flow
| Operating Cash Flow | -29.14M |
| Capital Expenditures | n/a |
| Free Cash Flow | -29.14M |
| FCF Per Share | -$2.23 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Annovis Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.09% |
| Shareholder Yield | -22.09% |
| Earnings Yield | -39.42% |
| FCF Yield | -26.70% |
Analyst Forecast
The average price target for Annovis Bio is $30.60, which is 266.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.60 |
| Price Target Difference | 266.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |